Oxford handbook of clinical haematology [[electronic resource] /] / Drew Provan ... [et al.]

• Record Nr.: UNINA9910456641103321
• Pubbl/distr/stampa: Oxford ; ; New York, : Oxford University Press, 2009
• ISBN: 0-19-959876-2; 1-283-58192-2; 9786613894373; 0-19-155169-4
• Edizione: [3rd ed.]
• Descrizione fisica: 1 online resource (880 p.)
• Collana: Oxford handbooks; Oxford medical publications
• Altri autori (Persone): ProvanDrew <1955->
• Disciplina: 616.1/5
• Soggetti: Blood - Diseases; Hematology; Electronic books.
• Lingua di pubblicazione: Inglese
• Formato: Materiale a stampa
• Livello bibliografico: Monografia
• Note generali: Description based upon print version of record.
• Nota di bibliografia: Includes bibliographical references and index.
• Nota di contenuto: Contents; Acknowledgements; Contributors; Symbols and abbreviations; 1 Clinical approach; History taking in patients with haematological disease; Physical examination; Splenomegaly; Lymphadenopathy; Unexplained anaemia; Patient with elevated haemoglobin; Elevated WBC; Reduced WBC; Elevated platelet count; Reduced platelet count; Easy bruising; Recurrent thromboembolism; Pathological fracture; Raised ESR; Serum or urine paraprotein; Anaemia in pregnancy; Thrombocytopenia in pregnancy; Prolonged bleeding after surgery; Positive sickle test (HbS solubility test); 2 Red cell disorders; The peripheral blood film in anaemiasAnaemia in renal disease; Anaemia in endocrine disease; Anaemia in joint disease; Anaemia in gastrointestinal disease; Anaemia in liver disease; Iron (Fe) deficiency anaemia; Vitamin B[sub(12)] deficiency; Folate deficiency; Other causes of megaloblastic anaemia; Anaemia in other deficiency states; Haemolytic syndromes; Genetic control of haemoglobin production; Sickling disorders; HbS-new therapies; Sickle cell trait (HbAS); Other ; sickling disorders; Other haemoglobinopathies; Unstable haemoglobins; Thalassaemias; α thalassaemia; β thalassaemia; Other thalassaemiasHereditary persistence of fetal haemoglobin; Hb patterns in haemoglobin disorders; Non-immune haemolysis; Hereditary spherocytosis; Hereditary elliptocytosis; Glucose-6-phosphate dehydrogenase (G6PD) deficiency; Pyruvate kinase (PK) deficiency; Other red cell enzymopathies; Drug-induced haemolytic anaemia; Methaemoglobinaemia; Microangiopathic haemolytic anaemia (MAHA); Acanthocytosis; Autoimmune haemolytic anaemia; Cold haemagglutinin disease (CHAD); Leucoerythroblastic anaemia; Aplastic anaemia; Paroxysmal nocturnal haemoglobinuria; Pure red cell aplasia; Iron (Fe) overloadTransfusion haemosiderosis; 3 White blood cell abnormalities; Neutrophilia; Neutropenia; Lymphocytosis and lymphopenia; Eosinophilia; Basophilia and basopenia; Monocytosis and monocytopenia; Mononucleosis syndromes; 4 Leukaemia; Acute myeloblastic leukaemia (AML); Acute lymphoblastic leukaemia (ALL); Chronic myeloid leukaemia (CML); Chronic lymphocytic leukaemia (B-CLL); Cell markers in chronic lymphoproliferative disorders; Prolymphocytic leukaemia (PLL); Hairy cell leukaemia and variant; Splenic marginal zone lymphoma (SMZL); Mantle cell lymphoma (MCL); Large granular lymphocyte leukaemia (LGLL)Adult T-cell leukaemia-lymphoma (ATL); Sézary syndrome (SS); 5 Lymphoma; Non-Hodgkin lymphoma (NHL); Indolent lymphoma; Treatment of indolent lymphoma; Aggressive lymphomas; Initial treatment of aggressive lymphomas; CNS lymphoma; Hodgkin lymphoma (HL, Hodgkin's disease); 6 Myelodysplasia; Myelodysplastic syndromes (MDS); Classification; Clinical features of MDS; Diagnostic criteria of MDS; Prognostic factors in MDS; Clinical variants of MDS; Management of MDS; Response criteria; Myelodysplastic/myeloproliferative diseases (MDS/MPD); 7 Myeloproliferative neoplasms (MPNs)
• Sommario/riassunto: The Oxford Handbook of Clinical Haematology continues to provide the essential knowledge needed in modern clinical practice for the diagnosis and management of patients with disorders of the blood. Major advances in the specialty, primarily within the malignant haematology area, have been reflected in this thoroughly revised new edition. Agencies such as NICE have influenced the prescribing of chemotherapeutic and other related drugs, and there have also been updates from theBritish Committee for Standards in Haematology and other guidelines for malignant disease, thrombosis and haemostasis.Th